Antila Lifesciences Private Limited Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Antila Lifesciences Private Limited Pharmaceutical Export Portfolio Dataset — 2 Products, $884.6K FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Antila Lifesciences Private Limited — Pharmaceutical Exporter Profile (2026) | 2 Products, $884.6K Trade | TransData Nexus

Antila Lifesciences Private Limited

Indian Pharmaceutical Exporter · Antimalarial & Antiparasitic Specialist · $884.6K Total Trade · DGFT Verified

Antila Lifesciences Private Limited is an Indian pharmaceutical exporter with a total trade value of $884.6K across 2 products in 2 therapeutic categories. Based on 33 verified export shipments from Indian Customs (DGFT) records, the company actively competes across multiple product segments. Top exports include Ivermectin ($511.4K), Tetracycline ($373.2K), .

Antila Lifesciences Private Limited — Export Portfolio & Destination Treemap

Antila Lifesciences Private Limited pharmaceutical export portfolio — 2 products across 2 therapeutic categories. Source: Indian Customs (DGFT).

Who is Antila Lifesciences Private Limited? — Company Overview & Market Position

Antila Lifesciences Private Limited, established on December 21, 2010, is a privately held pharmaceutical company headquartered in Ahmedabad, Gujarat, India. The company specializes in the manufacturing and export of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections, across various therapeutic categories. As of March 2026, Antila Lifesciences has an authorized capital of ₹5 million and a paid-up capital of ₹1.67 million. The Corporate Identification Number (CIN) is U24230GJ2010PTC063306, and the company is registered under the Registrar of Companies, Ahmedabad.

The company's registered office is located at 814, Devpath B/H Lal Bunglow Off C.G. Road, Navrangpura, Ahmedabad, Gujarat, 380006. Antila Lifesciences operates as a non-government company limited by shares and is unlisted. The latest Annual General Meeting (AGM) was held on September 30, 2025, with the balance sheet filed on March 31, 2025.

What Does Antila Lifesciences Private Limited Export? — Product Portfolio Analysis

Top Products by Export Value

1Ivermectin$511.4K 2

Product Portfolio — Top 2 by Export Value

Antila Lifesciences Private Limited exports 2 pharmaceutical products across 2 therapeutic categories.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Ivermectin	Antimalarial & Antiparasitic	$511.4K	22	5.9%	3
2	Tetracycline	Antibiotics	$373.2K	11	2.2%	8

Antila Lifesciences Private Limited exports 2 pharmaceutical products across 2 therapeutic categories with a total export value of $884.6K. The top category is Antimalarial & Antiparasitic (57.8% of portfolio), followed by Antibiotics (42.2%), indicating a concentrated portfolio with the top 5 products accounting for 100.0% of total export value.

Antila Lifesciences Private Limited — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

Antila Lifesciences operates a WHO-GMP certified state-of-the-art manufacturing facility in Ahmedabad, Gujarat. The facility is equipped to produce a wide range of pharmaceutical formulations, including tablets, capsules, syrups, and injections, adhering to international quality standards. The company's manufacturing operations are integrated with its marketing and distribution channels, enabling efficient production and export processes.

3Key Leadership

The leadership team at Antila Lifesciences comprises three directors:

Rutwa Vijaykumar Shah: Director since December 21, 2010.
Parth Mayurbhai Shah: Director since December 21, 2010.
Sanjay Jashwantlal Shah: Director since December 21, 2010.

These directors have been instrumental in steering the company's growth and expansion in the pharmaceutical export sector.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Antila Lifesciences Private Limited Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Antila Lifesciences has established a presence in several regulated markets, including the United States, European Union, United Kingdom, Australia, and Japan. The company has obtained necessary regulatory approvals and certifications to export its pharmaceutical formulations to these regions. Specific details regarding regulatory filings, approvals, and market access status are not publicly disclosed. However, the company's adherence to WHO-GMP standards and its commitment to quality manufacturing practices support its ability to meet the stringent requirements of these markets.

2Emerging Markets

Antila Lifesciences has expanded its reach to emerging markets in Africa, Latin America, and Southeast Asia. The company's compliance with WHO-GMP standards facilitates its entry into these regions, enabling access to a broader customer base. While specific market penetration details are not publicly available, the company's global reach and diverse product portfolio position it well to capitalize on opportunities in these emerging markets.

3Geographic Strategy

Antila Lifesciences Private Limited — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Specific details regarding Antila Lifesciences' FDA facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, and inspection history are not publicly disclosed. However, the company's adherence to WHO-GMP standards and its state-of-the-art manufacturing facility suggest a commitment to meeting international regulatory requirements, including those of the FDA.

2WHO & EU GMP

Antila Lifesciences' manufacturing facility is WHO-GMP certified, indicating compliance with the World Health Organization's Good Manufacturing Practices. This certification underscores the company's commitment to producing high-quality pharmaceutical formulations. Specific details regarding EU GMP certificates and EDQM status are not publicly available.

3CDSCO & Indian Regulatory

Antila Lifesciences holds manufacturing licenses from the Central Drugs Standard Control Organisation (CDSCO), ensuring compliance with Indian regulatory standards for pharmaceutical manufacturing. The company has also obtained necessary approvals from state drug controllers and export No Objection Certificates (NOCs), facilitating its export operations. Specific details regarding these approvals are not publicly disclosed.

Antila Lifesciences Private Limited — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

Antila Lifesciences operates in a competitive pharmaceutical export market, facing competition from both domestic and international companies. While specific market share comparisons and head-to-head analyses are not publicly available, the company's WHO-GMP certified manufacturing facility and diverse product portfolio position it as a competent player in the industry. The company's focus on quality and customer satisfaction enhances its competitive edge.

2Key Differentiators

Antila Lifesciences' key differentiators include its WHO-GMP certified manufacturing facility, a broad range of pharmaceutical formulations, and a commitment to quality and customer satisfaction. The company's adherence to international quality standards and its focus on continuous improvement and innovation contribute to its competitive advantages.

3Strategic Position

Antila Lifesciences' current strategic direction focuses on expanding its presence in both regulated and emerging markets by leveraging its WHO-GMP certified manufacturing facility and diverse product portfolio. The company's future outlook includes exploring new growth opportunities through innovative formulations and maintaining a strong commitment to quality and customer satisfaction.

Buyer Due Diligence Brief — Evaluating Antila Lifesciences Private Limited as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

Antila Lifesciences has demonstrated a consistent track record in pharmaceutical manufacturing, with a focus on quality and customer satisfaction. The company's export volume and consistency are supported by its WHO-GMP certified manufacturing facility and adherence to international quality standards. Reliability indicators include a dedicated and trained workforce, a state-of-the-art manufacturing facility, and a commitment to continuous improvement and innovation.

2Certifications to Verify

Importers should verify the following certifications when considering Antila Lifesciences as a supplier:

FDA Facility Registration: To confirm the company's registration with the U.S. Food and Drug Administration.
WHO-GMP Certification: To ensure compliance with the World Health Organization's Good Manufacturing Practices.
EU GMP Certificate: To verify adherence to European Union Good Manufacturing Practices.

Frequently Asked Questions — Antila Lifesciences Private Limited

How many pharmaceutical products does Antila Lifesciences Private Limited export from India?

Antila Lifesciences Private Limited exports 2 pharmaceutical products across 2 therapeutic categories. The top exports are Ivermectin ($511.4K), Tetracycline ($373.2K). Total export value is $884.6K.

What is Antila Lifesciences Private Limited's total pharmaceutical export value?

Antila Lifesciences Private Limited's total pharmaceutical export value is $884.6K, based on 33 verified shipments recorded in Indian Customs (DGFT) data.

What therapeutic categories does Antila Lifesciences Private Limited cover?

Antila Lifesciences Private Limited exports across 2 therapeutic categories. The largest are Antimalarial & Antiparasitic (57.8%, 1 products), Antibiotics (42.2%, 1 products).

Get Full Antila Lifesciences Private Limited Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.